ROE of Alnylam Pharmaceuticals, Inc. (ALNY) stands at

(NASDAQ:ALNY). Analysts are projecting that the stock will reach $66.40 on a short term (1 year) basis.

Growth Estimate for Intercontinental Exchange, Inc.

For the quarter ending 11/02/2016, The Analyst projected that the company could deliver EPS of -1.14 while the company provided its Actual EPS of -1.21 showing a difference of -0.07 Percent between the Estimated and Actual EPS.

Steel Dynamics, Inc. (STLD) have shown a high EPS growth of 5.00% in the last 5 years and has earnings decline of 389.30% yoy. In terms of performance, year to date, the stock is 7.44%.

Several sell side analysts reviewed their recommendations on Alnylam Pharmaceuticals, Inc. (NYSE:ICE) for the current quarter. According to their observations and findings, the stock could provide a high EPS of $-0.92/share and a Low EPS of $-1.59/share. JMP Securities set a $69.00 price target on Alnylam Pharmaceuticals and gave the company a "buy" rating in a research note on Friday, February 3rd.

The Stock now has the market capitalization of $4.75 Billion, P/E (price to earnings ttm) of 0 and Weekly volatility of 6.17% and monthly volatility of 5.22% respectively. The stock's market capitalization is $4.75 billion. The stock appeared $40.02 above its 52-week highs and is up 6.95% for the last five trades. The stock's current distance from 20-Day Simple Moving Average (SMA20) is 4.35% where SMA50 and SMA200 are 5.78% and 11.52% respectively. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $80.11.

The Average Volume of the company is 4.87 Million, while the Relative Volume of the company is 1.78. Arrowpoint Asset Management LLC now owns 692,736 shares of the biopharmaceutical company's stock worth $25,936,000 after buying an additional 301,877 shares during the last quarter.

The Company now has Insider ownership of 0.5 Percent and Institutional Ownership of 94.7 Percent.

Many research firms have provided their ratings on Alnylam Pharmaceuticals, Inc. (ALNY) where 0 analyst have rated the stock as Strong Buy, 0 analysts said it's a Buy, 0 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell. The highest and lowest price target given by the brokerage firms to the equity are $118 and $39, respectively. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Considering the performance, Alnylam Pharmaceuticals, Inc. Thus the company showed an Earnings Surprise of 1.5 Percent. The company's quarterly performance represents an optimistic momentum of 26.16 percent, with a surge of 14.5 percent in the stock price over the last one month. The stock is now trading with a distance of 20-Day Simple Moving Average (SMA20) of 10.2%. The stock recently closed its previous session at $55.25 by showing a percentage change of 1.41% from its previous day closing price of $54.48.

Alnylam Pharmaceuticals, Inc. (ALNY) is now showing its ROA (Return on Assets) of -31.1%. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.34) by $0.02. The company had revenue of $17.50 million for the quarter, compared to analyst estimates of $10.66 million.

Otras noticias